Research programme: obesity therapy - Halsa Pharmaceuticals

Drug Profile

Research programme: obesity therapy - Halsa Pharmaceuticals

Alternative Names: ZAG; Zinc-α2-glycoprotein

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Halsa Pharmaceuticals
  • Class Recombinant proteins
  • Mechanism of Action Glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA (Parenteral, Injection)
  • 27 Oct 2009 Pharmacodynamics data from animal studies in obesity released by Halsa Pharmaceuticals
  • 15 Oct 2009 Halsa receives $US0.75 million from Texas Emerging Technology Fund (TETF)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top